Active, Not Recruiting
A Phase 3 Study to Evaluate the Immunogenicity and Safety of Walvax's PCV13-TT as Compared to Pfizer's PCV13
NCT05934890
- Conditions
- Bacterial Infections, Bacterial Infections and Mycoses, Gram-Positive Bacterial Infections, +4 more
- Locations
-
- RSUP Prof. Dr. I.G.N.G Ngoerah Denpasar, Bali, Indonesia
- Ilmu Kesehatan anak FKUI RSCM Jakarta Pusat, Jakarta Special Capital Region, Indonesia